Movement Alert|Viking Therapeutics Falls 8.1% in Regular Trading, Market Continues to Digest Wider-Than-Expected Quarterly Loss

Market Focus11-05

On November 5, Viking Therapeutics fell 8.1% in Regular Trading to $25.695/share, with turnover of $29.7442 million.

The clearest recent catalyst in public information is continued digestion of the company’s late-October quarterly report. Viking Therapeutics reported third-quarter EPS of $1.55 loss, wider than consensus expectations for a $1.06 to $1.07 loss, even though the company also highlighted positive obesity-study data and a cash balance of about $960 million.

That makes the move primarily earnings-driven: the reported loss came in worse than expected, and recent market coverage linked share-price weakness to investors focusing on that earnings miss rather than pipeline progress. Earlier supportive items, including Phase 3 advancement for oral VK2735 and a Buy initiation with a $94 price target, provide background but do not appear to be the most immediate driver of this session’s decline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment